Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growt

The U.S. Food and Drug Administration (FDA) recently approved Teva Pharmaceutical Industries Ltd. (N

FDA approves Teva's Weltruza, a once-monthly injectable for adults with schizophrenia, eliminati

Teva Pharmaceutical Industries NYSE: TEVA said the U.S. Food and Drug Administration has approved WE

Teva said on Friday it ​had received approval ‌from the US Food and Drug ​Administration for ​its We

WELTRUZA clinical trial results demonstrated improvement in symptoms (PANSS), significant reduction

WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthl

Based on a post hoc analysis, a majority of participants (~70%) experienced clinically meaningful ti

The published review examines dopamine’s role in tic generation and how approved and investigational

Analysts initiated bullish coverage on Vita Coco, Toll Brothers, Civeo, Teva and Kura Oncology, with

TD Cowen initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announc

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Dru

Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with

New data revealed that healthcare providers prioritize drowsiness risk, duration of available data d

New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables

In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half o

The U.S. FDA approved Ocrevus for paediatric RMS patients in May 2026. A final decision from the Eur

Teva Pharmaceutical Industries had a busy week that included a major debt refinancing, a NYSE tradin

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it s

Leerink Partners analyst Daniel Clark initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA)

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises t

Teva reports positive Phase 2a results for TEV '408, successfully preventing gluten-induced inte

Teva Pharma is trading higher after announcing positive topline results from a Phase 2a study of TEV

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced positive topline results f

Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),

https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-wi

BioXcel Chapter 11 sends BTAI shares sharply lower as Teva becomes the stalking horse bidder for IGA

Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch gen

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it and its subsidiary, Aurinia Pharm

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),

Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweigh

Teva revenue tops estimates despite an earnings miss. The company raises 2026 sales guidance and hig

Teva Pharmaceutical Indus (NYSE:TEVA) lowers FY2026 Adj EPS guidance from $2.57-$2.77 to $1.91-$2.11

Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.02 per share which missed th

Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overw

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE:AN

Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to O

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE: TEVA) and Samsung Bioepis Co., Ltd. today ann

Bill Ackman is bullish on Israel. Here's why he thinks investors should watch the region.

Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmen

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to advance its TEV-’

https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-

New analysis from the IMPACT-TD Registry demonstrates that treatment with AUSTEDO and AUSTEDO XR led

New real-world survey data reveal the daily impact of Huntington's disease (HD) chorea, with ove

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of AHZANTIVE (a

The olanzapine long-acting injectable (TEV-'749) is designed to deliver the efficacy of olanzapi

The IMPACT-TD findings revealed:A majority of participants, regardless of age, reported a moderate t